Nanjing, China/Gaithersburg, USA | August, 26 2025, TransThera Sciences (Nanjing), Inc. ('TransThera' or 'the Company'; Stock Code: 2617.HK) announced that pursuant to the quarterly review results of the Hang Seng Index Series published by Hang Seng Indexes Company Limited on August 22, 2025, the Company has been selected and will be included as a constituent of the Hang Seng Index Series, including but not limited to the following, with effect from September 8, 2025:

1. Hang Seng Composite Index;

2. Hang Seng Composite Industry Index – Healthcare;

3. Hang Seng Composite MidCap & SmallCap Index;

4. Hang Seng Composite SmallCap Index;

5. Hang Seng Healthcare Index;

6. Hang Seng Innovative Drug Index;

7. Hang Seng SCHK Innovative Drug Index;

8. Hang Seng SCHK Innovative Drug Select Index; and

9. Hang Seng SCHK Pharmaceuticals & Biotechnology (Investable) Index.

About TransThera

TransThera is a clinical demand-oriented, registrational clinical-stage biopharmaceutical company focusing on discovering and developing innovative small molecule therapies for oncology, inflammatory and cardiometabolic diseases. Further aided by in-depth study of translational medicine and drug design, TransThera aims to develop first-in-class or best-in-class drug candidates strategically positioned to meet urgent clinical needs on a global scale. For more information, please visit www.transthera.com